98968-72-0

Basic information

• Product Name: N-BOC-2-FLUOROANILINE
• Synonyms: N-BOC-2-FLUOROANILINE;Carbamic acid, (2-fluorophenyl)-, 1,1-dimethylethyl ester (9CI);tert-Butyl2-fluorophenylcarbamate;1-BOC-Amino-2-fluorobenzene;CarbaMic acid, N-(2-fluorophenyl)-, 1,1-diMethylethyl ester;2-methyl-2-propanyl (2-fluorophenyl)carbamate
• CAS NO: 98968-72-0
• Molecular Formula: C₁₁H₁₄FNO₂
• Molecular Weight: 211.2327632
• Product Categories: N-BOC;API intermediates;Miscellaneous;amine|alkyl Fluorine| carboxylic ester
• Mol File: 98968-72-0.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 230.1 °C at 760 mmHg
• Flash Point: 92.9 °C
• Appearance: /
• Density: 1.156 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-BOC-2-FLUOROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-2-FLUOROANILINE(98968-72-0)
• EPA Substance Registry System: N-BOC-2-FLUOROANILINE(98968-72-0)

Safety Data

• Hazardous Substances Data: 98968-72-0(Hazardous Substances Data)

Usage

General Description

N-BOC-2-Fluoroaniline is a chemical compound with the molecular formula C15H20N2O3F. It is a derivative of aniline with a 2-fluoro substituent and a BOC protective group attached to the amino group. N-BOC-2-FLUOROANILINE is commonly used as an intermediate in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. The BOC protective group helps to control the reactivity of the amino group, allowing for selective reactions to occur at other functional groups within the molecule. N-BOC-2-Fluoroaniline is a valuable building block for the synthesis of various biologically active compounds and is utilized in research and development processes in the pharmaceutical industry.

Upstream product

• 348-54-9 2-Fluoroaniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 

Downstream Products

• 138343-78-9 N-(tert-butoxycarbonyl)-2-fluoro-6-methylaniline 
• 141940-30-9 2-(tert-Butoxycarbonylamino)-3-fluoro-benzoic acid 
• 844891-30-1 tert-butyl N-(2-formyl-6-fluorophenyl)carbamate 
• 908600-92-0 (2-fluoro-6-iodophenyl)carbamic acid tert-butyl ester 
• 908600-90-8 tert-butyl 2-[(E)-2-chloroethenyl]-6-fluorophenylcarbamate 
• 908600-89-5 tert-butyl 6-fluoro-2-[2-(trimethylsilyl)ethynyl]phenylcarbamate 
• 387-44-0 7-fluoro-1H-indole 
• 854538-99-1 {2-Fluoro-6-[(1S,4R)-4,7,7-trimethyl-3-oxo-bicyclo[2.2.1]hept-(2E)-ylidenemethyl]-phenyl}-carbamic acid tert-butyl ester 
• 854539-01-8 {2-[(5S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,4,5,6,7,8,9,10,11,12,13,14,15,17-tetradecahydro-cyclopenta[a]phenanthren-(16E)-ylidenemethyl]-6-fluoro-phenyl}-carbamic acid tert-butyl ester 
• 854538-94-6 2-amino-3-fluorobenzaldehyde 
• 317-20-4 7-fluoro-1H-indole-2,3-dione 
• 71294-03-6 7-fluoro-1,3-dihydro-indol-2-one 
• 138344-06-6 (2-tert-Butoxycarbonylamino-3-fluoro-phenyl)-acetic acid 
• 144851-60-5 6-fluoro-2-methylthioaniline 

Relevant articles and documents

GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES

Conjugates comprising GalNAc moiety and a TGFβR1 inhibitor are provided. In some embodiments, the conjugates are useful for the treatment of viral infections, cancer, and fibrosis.

A suitable hydrobromidum fertile for method for synthesizing west sandbank industrial production (by machine translation)

The invention provides a novel method for preparing vortioxetine hydrobromide, and belongs to the technical field of medicine synthesis. The method uses 2-fluoroaniline as a starting material to prepare the clinical medicinal vortioxetine hydrobromide by Boc protection, condensation, deprotection condensation, cyclization and other 4 steps of reaction. The method has the advantages of easy obtained raw material, low price, simple synthesis operation, mild reaction condition, easy control, no high pressure, good reaction selectivity, high yield and suitability for industrial production.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.